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After tooth extraction, a marked resorption of the alveolar ridge occurs due to the tooth‐bundle bone‐dependent relationship (Araujo & Lindhe [2005](#jcpe12658-bib-0002){ref-type="ref"}), both horizontally and vertically. A more recent study (Chappuis et al. [2013](#jcpe12658-bib-0007){ref-type="ref"}), with analysis of the alveolar ridge after tooth extraction via CBCT, reported even 3.5 times more severe bone resorption than the findings described in the existing literature. These changes in the alveolar ridge after tooth extraction have to be taken into account when implants are planned. Farmer & Darby ([2014](#jcpe12658-bib-0015){ref-type="ref"}) concluded that the majority of the implants placed in aesthetic zones required simultaneous bone augmentation due to the resorption in the mid‐buccal aspect.

Several bone substitutes and/or procedures have been described in the literature but no specific technique neither for sinus augmentation nor for guided bone regeneration (GBR) procedures have been strongly recommended (McAllister & Haghighat [2007](#jcpe12658-bib-0030){ref-type="ref"}, Vignoletti et al. [2014](#jcpe12658-bib-0044){ref-type="ref"}). The use of growth factors has also been proposed as adjuvant of bone grafting. Jung et al. ([2008](#jcpe12658-bib-0020){ref-type="ref"}) concluded that bone morphogenetic proteins (BMP‐2, BMP‐7), growth‐differentiation factor‐5 (GDF‐5), platelet‐derived growth factor (PDGF) and parathyroid hormone (PTH) might stimulate local bone augmentation during ridge preservation procedures. For sinus augmentation, also BMP‐2 has been proposed as adjuvant of conventional techniques (Lin et al. [2015](#jcpe12658-bib-0025){ref-type="ref"}).

Platelet concentrates were suggested for bone augmentation procedures because of their constant release of growth factors. Platelet concentrates were initially used as fibrin glue to improve wound healing (Matras [1970](#jcpe12658-bib-0028){ref-type="ref"}). Later, the first generation of platelet concentrates, which included platelet‐rich plasma (PRP) (Marx [2001](#jcpe12658-bib-0027){ref-type="ref"}) and plasma rich in growth factors (PRGF) (Anitua [1999](#jcpe12658-bib-0001){ref-type="ref"}), were developed. However, they had some disadvantages: expensive, operator dependent and extended production time. The second generation of platelet concentrates appeared to improve and ease the use of this technique (Choukroun [2001](#jcpe12658-bib-0008){ref-type="ref"}, Dohan et al. [2006a](#jcpe12658-bib-0012){ref-type="ref"}). Leucocyte‐ and platelet‐rich fibrin (L‐PRF) belongs to the second generation of platelet concentrates (Dohan et al. [2014](#jcpe12658-bib-0011){ref-type="ref"}). For its preparation, 9--10 ml blood is withdrawn from the patient in plastic/glass‐coated tubes through venepuncture. No anticoagulants or additives are used. The blood is immediately centrifuged at 400 *g* during 10--12 min. After centrifugation, three layers are obtained: at the bottom, red blood corpuscles (RBC); at the top, platelet‐poor plasma (PPP); and in the middle, a fibrin clot (L‐PRF). L‐PRF contains a dense fibrin fibre network where platelets and leucocytes are enmeshed and it can serve as scaffold for other type of cells due to its favourable mechanical properties (Rowe et al. [2007](#jcpe12658-bib-0036){ref-type="ref"}, Khorshidi et al. [2016](#jcpe12658-bib-0022){ref-type="ref"}). Its content in leucocytes and platelets results in a constant release of growth factors such as PDGF, transforming growth factor (TGF), vascular endothelial growth factor (VEGF) and insulin‐like growth factor (IGF) for 7--14 days (Dohan et al. [2006b](#jcpe12658-bib-0013){ref-type="ref"}, Schär et al. [2015](#jcpe12658-bib-0037){ref-type="ref"}). Its biological characteristics could also improve/facilitate the osseointegration process (Öncü et al. [2016](#jcpe12658-bib-0033){ref-type="ref"}).

The main aim of this systematic review was to analyse the capacity of L‐PRF to promote bone regeneration in systemically healthy patients (ASA I). Its influence on potential adverse events after surgery was considered as a secondary aim.

Materials and Methods {#jcpe12658-sec-0006}
=====================

This systematic review follows the guidelines of the Belgian Centre for Evidence‐Based Medicine (CEBAM), Belgian Branch of the Dutch Cochrane Centre. It was conducted in accordance with the Transparent Reporting of Systematic Reviews and Meta‐analyses (Moher et al. [2009](#jcpe12658-bib-0031){ref-type="ref"}, [\[Link\]](#jcpe12658-bib-0035){ref-type="ref"}).

Focused PICO question {#jcpe12658-sec-0007}
---------------------

The following statements were used to conduct the systematic search:

1Population (P) = systemically healthy humans (ASA I) with lack of alveolar bone and/or with need of implant therapy.2Intervention (I) = use of L‐PRF (protocol 2700 r.p.m./12 min. or 3000 r.p.m./10 min.) as biomaterial (alone or in combination with a graft material) in guided bone regeneration techniques and implant surgery.3Comparison (C) = traditional techniques using bone substitute (xenograft, allograft, etc.) with/without collagen membrane or connective tissue graft.4Outcome (O) = alveolar bone regeneration (reported as newly formed bone (%), soft tissue and bone healing (reported as healing index scores, bone resorption in mm and/or in technetium‐99 m methylene diphosphonate uptake) and implant osseointegration (reported as ISQ values and/or marginal bone loss in mm).

A PICO question was created to define the search strategy: *Does L‐PRF promote regeneration in systemically healthy patients (ASA I) during guided bone regeneration techniques and implant surgery compared to traditional techniques?*

Search strategy {#jcpe12658-sec-0008}
---------------

An electronic search was performed in three Internet databases: the National Library of Medicine, Washington, DC (MEDLINE‐PubMed), EMBASE (Excerpta Medical Database by Elsevier), and Cochrane Central Register of Controlled Trials (CENTRAL). The search terms were defined by combining (Mesh Terms OR Key Words) from "Population" AND (Mesh Terms OR Key Words) from "Intervention", as shown in Table S1.

No language or time restrictions were applied in the first search. However, only studies written in English were included for selection. The search was limited to human studies. The last electronic search was performed on the 31st of July 2015.

This search was enriched by hand searches, citation screening and expert recommendations. All reference lists of selected papers as well as related reviews were scanned for possible additional studies.

Screening and selection {#jcpe12658-sec-0009}
-----------------------

Two reviewers (A.C., N.M.) screened independently the titles and abstract obtained from the first search. When publications did not meet the inclusion criteria, they were excluded upon reviewer\'s agreement. Any disagreement between the two reviewers was resolved by discussion. All full texts of the eligible articles were examined by both reviewers. The articles that fulfilled all selection criteria were processed for data extraction. The two most accepted protocols for the preparation of L‐PRF (2700 r.p.m./12 min. or 3000 r.p.m./10 min.) were included. The inclusion and exclusion criteria are summarized in Table S2.

Assessment of heterogeneity {#jcpe12658-sec-0010}
---------------------------

The heterogeneity of the included studies was evaluated based on following factors: (1) study design and follow‐up duration, (2) subject characteristics and smoking habits, and (3) surgical protocol: (a) centrifugation protocol (2700 r.p.m./12 min. or 3000 r.p.m./10 min.), (b) ml blood used to prepare L‐PRF and (c) number of clots/membranes (if used).

Data extraction and quality assessment {#jcpe12658-sec-0011}
--------------------------------------

Data extraction was performed for the included studies. All variables analysed in each study were processed. Where possible, a meta‐analysis was performed.

Both reviewers (A.C., N.M.) independently performed the quality assessment using the Cochrane Collaboration\'s tool for assessing risk of bias. Six quality criteria were verified: (1) sequence generation or randomization component, (2) allocation concealment, (3) blinding of participants, personnel and outcome assessors, (4) incomplete/missing outcome data, (5) selective outcome reporting and (6) other sources of bias. In case of any doubt, the authors were contacted for clarification or to provide missing information. Each study was classified into the following groups: low risk of bias if all quality criteria were judged as "present", moderate risk of bias if one or more key domains were "unclear", and high risk of bias if one or more key domains were "absent".

Results {#jcpe12658-sec-0012}
=======

Search and selection {#jcpe12658-sec-0013}
--------------------

As a result of the electronic and hand search, 603 articles were obtained, of which 154 were duplicate and consequently removed (Fig. [1](#jcpe12658-fig-0001){ref-type="fig"}). A total of 449 articles were included for title and abstract screening. From those, 26 articles were included for full text review. Twelve articles were excluded after full text screening, which was conducted independently by two reviewers (A.C., N.M.) (Table S3). Fourteen randomized control trials (RCTs) fulfilled the inclusion criteria and were included for analysis.

![PRISMA flow diagram.](JCPE-44-225-g001){#jcpe12658-fig-0001}

The included articles were classified into three subgroups, depending on the indication for the use of L‐PRF (Tables [1](#jcpe12658-tbl-0001){ref-type="table-wrap"}, [2](#jcpe12658-tbl-0002){ref-type="table-wrap"}, [3](#jcpe12658-tbl-0003){ref-type="table-wrap"}):

###### 

L‐PRF for sinus floor elevation. Papers have been arranged by sub‐applications (L‐PRF as coverage of lateral window and L‐PRF bone quality)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors (year)                                                  Study design, Duration   No. of participants baseline (end), gender, **a**ge (mean/range), smoking (?, No, Yes)   Groups C: control *T*: test                       L‐PRF preparation                                     Surgical protocol                 Results
  --------------------------------------------------------------- ------------------------ ---------------------------------------------------------------------------------------- ------------------------------------------------- ----------------------------------------------------- --------------------------------- --------------------------------------------------------------------------------------------------------------------------
  L‐PRF as coverage of lateral window                                                                                                                                                                                                                                                                                         

  Gassling et al. ([2013](#jcpe12658-bib-0016){ref-type="ref"})   RCT\                     6 -- (6)\                                                                                C: *n* = 6, Bio‐Oss^®^ + Bio‐Guide^®^ membrane\   Hardware: ?\                                          1 L‐PRF membrane + Bio‐Oss^®^\    **L‐PRF as coverage of lateral window**\
                                                                  Split‐mouth\             Gender: ?\                                                                               T: *n* = 6, Bio‐Oss^®^ + L‐PRF membrane           Setting: 400 g/12 min.                                LW\                               NSSD in mean new‐formed bone 17.0% and 17.2% for L‐PRF and collagen sites respectively.\
                                                                  Single‐blind\            Mean age: 61\                                                                                                                                                                                    no imm. impl.\                    NSSD in mean residual bone‐substitute (15.9% and 17.3% respectively).
                                                                  5 months                 Range: 54--69\                                                                                                                                                                                   10 ml blood/clot                  
                                                                                           Smoking: ?                                                                                                                                                                                                                         

  L‐PRF bone quality                                                                                                                                                                                                                                                                                                          

  Zhang et al. ([2012](#jcpe12658-bib-0046){ref-type="ref"})      RCT\                     10 -- (10)∇\                                                                             C: *n* = 5, SL + Bio‐Oss^®^\                      Hardware: [a](#jcpe12658-note-0002){ref-type="fn"}\   1 L‐PRF membrane + Bio‐Oss^®^\    **L‐PRF bone quality**\
                                                                  Parallel\                2 ♀, 8 ♂\                                                                                T: *n* = 6, SL + Bio‐Oss^®^ + L‐PRF               Setting: 300 g/10 min.                                LW\                               NSSD in bone morphological characteristics in both groups.\
                                                                  Not blind\               Mean age: C: 46, T: 43\                                                                                                                                                                          no imm. impl.\                    L‐PRF group had 1.4 times higher percentage of newly formed bone than control group (18.3 ± 5.6% *versus* 12.95 ± 5.3%).
                                                                  6 months                 Range: C: 37--53, T: 30--49\                                                                                                                                                                     10 ml blood/clot                  
                                                                                           Smoking: ?                                                                                                                                                                                                                         

  Tatullo et al. ([2012](#jcpe12658-bib-0042){ref-type="ref"})    RCT\                     60 -- (60)\                                                                              \*Early implant surgery: *n* = 20\                Hardware: ?\                                          2 L‐PRF membranes + Bio‐Oss^®^\   **L‐PRF bone quality**\
                                                                  Parallel\                48 ♀, 12 ♂\                                                                              ‐ *n* = 6: SL + Bio‐Oss^®^\                       Setting: 3000 r.p.m./10 min.                          TT + piezosurgery\                NSSD in ISQ mean values.\
                                                                  Single‐ blind\           Mean age: ?\                                                                             ‐ *n* = 10: SL + Bio‐Oss^®^ + L‐PRF\                                                                    no imm. impl.\                    L‐PRF showed histologically faster bone formation (106 days compared to 120--150 days)
                                                                  5 months                 Range: 43--62\                                                                           ‐ *n* = 4: bilateral atrophy:\                                                                          10 ml blood/clot                  
                                                                                           Smoking: No                                                                              • Bio‐Oss^®^\                                                                                                                             
                                                                                                                                                                                    • Bio‐Oss^®^ + L‐PRF\                                                                                                                     
                                                                                                                                                                                    \*Intermediate: *n* = 20, idem\                                                                                                           
                                                                                                                                                                                    \*Late: *n* = 20, idem                                                                                                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

∇: 10 participants but 1 subject received two sinus floor elevations: ^a^Labofuge 300, Kendro Laboratory Products GmbH, Osterrode, Germany. C, control group; imm. impl., immediate implant; ISQ, implant stability quotient; L‐PRF, leucocyte‐ and platelet rich fibrin; LW, Lateral window; NSSD, no statistical significant different; RCT, randomized control trials; SL, sinus lift; *T*, test group; TT, Transalveolar technique.

John Wiley & Sons, Ltd

###### 

L‐PRF for alveolar ridge preservation. Papers have been arranged by sub‐applications (L‐PRF *versus* "natural healing": bone quality, L‐PRF *versus* PRP, L‐PRF pain, L‐PRF uptake technetium‐99 m methylene diphosphonate)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors (year)                                                          Study design, Duration   No. of participants baseline (end), gender, age (mean/range), smoking (?, No, Yes)   Groups C: control *T*: test            L‐PRF preparation                                      Surgical protocol      Results
  ----------------------------------------------------------------------- ------------------------ ------------------------------------------------------------------------------------ -------------------------------------- ------------------------------------------------------ ---------------------- --------------------------------------------------------------------------------------------------------------------------------------------------
  L‐PRF *versus* natural healing: bone quality                                                                                                                                                                                                                                                               

  Singh et al. ([2012](#jcpe12658-bib-0039){ref-type="ref"})              RCT\                     20 -- (20)\                                                                          20 bilateral impacted 3rd molar:\      Hardware: ?\                                           1 L‐PRF clot\          **L‐PRF** ***versus*** **natural healing**\
                                                                          Split‐mouth\             10 ♀, 10 ♂\                                                                          C: *n* = 20, no filling\               Setting: 3000 r.p.m./10 min.                           0 L‐PRF membrane\      SS better Healing Index scores for L‐PRF group (at 7th day *p* = 0.0015)\
                                                                          Not blind\               Mean age: 32\                                                                        T: *n* = 20, L‐PRF filling                                                                    5--10? ml blood/clot   NSSD in trabecular bone formation\
                                                                          3 months                 Range 18--50\                                                                                                                                                                                             SS higher bone density at 12 weeks for L‐PRF group
                                                                                                   Smoking: No                                                                                                                                                                                               

  Hauser et al. ([2013](#jcpe12658-bib-0019){ref-type="ref"})             RCT\                     23 -- (22)\                                                                          Premolar extractions:\                 Hardware: ?\                                           1 L‐PRF clot\          **L‐PRF** ***versus*** **natural healing**\
                                                                          Parallel\                14 ♀, 9 ♂\                                                                           C: *n* = 7\                            Setting: 2700 r.p.m./12 min.                           ? L‐PRF membrane\      Mean crestal bone loss: control group 0.43 ± ? mm,\
                                                                          Double‐blind\            Mean age: 47\                                                                        T~1~: *n* = 9, L‐PRF filling\                                                                 8 ml blood/clot        L‐PRF group 0.06 ± ? mm, and L‐PRF + flap 0.42 ± ?\
                                                                          8 weeks                  Range: 22--75\                                                                       T~2~: *n* = 6, L‐PRF filling + flap                                                                                  Mm (*p* \< 0.05)\
                                                                                                   Smoking: ?                                                                                                                                                                                                L‐PRF + Flap: invasive surgical procedure seemed to neutralize advantages of L‐PRF

  Suttapreyasri & Leepong ([2013](#jcpe12658-bib-0040){ref-type="ref"})   RCT\                     8 -- (8)\                                                                            10 bilateral premolar extractions:\    Hardware: [a](#jcpe12658-note-0004){ref-type="fn"}\    1 L‐PRF clot\          **L‐PRF** ***versus*** **natural healing**\
                                                                          Parallel\                5 ♀, 3 ♂\                                                                            C: *n* = 10, no filling\               Setting: 3000 r.p.m./10 min.                           0 L‐PRF membrane\      NSSD between both groups for soft‐tissue healing (*p* \> 0.05)\
                                                                          Split‐mouth\             Mean age: 22 ± 2\                                                                    T: *n* = 10, L‐PRF filling                                                                    10 ml blood/clot       less buccal/lingual resorption for L‐PRF group (1.9 ± 1.1 mm *versus* 2.6 ± 0.7 mm, *p* \< 0.05)\
                                                                          8 weeks                  Range 20.3--27.6\                                                                                                                                                                                         NSSD for radiographic evaluation (at mesial and distal site): L‐PRF 0.7 mm/1.23 mm, control 1.33 mm/1.1 mm.
                                                                                                   Smoking: ?                                                                                                                                                                                                

  Kumar et al. ([2015](#jcpe12658-bib-0023){ref-type="ref"})              RCT\                     31 -- (31)\                                                                          3rd molar extractions:\                Hardware: ?\                                           1 L‐PRF clot\          **L‐PRF** ***versus*** **natural healing**\
                                                                          Parallel\                Gender: ?\                                                                           C: *n* = 15, no filling\               Setting: 3000 r.p.m./10 min.                           0 L‐PRF membrane\      SS more PD reduction (distal 2nd molar) in L‐PRF group (1.5 ± ? mm *versus* 0.5 ± ? mm).\
                                                                          Single‐blind\            Mean age: 26.1\                                                                      T: *n* = 16, L‐PRF filling                                                                    5 ml blood/clot        NSSD for bone density after 3 months (*p* \> 0.05)\
                                                                          3 months                 Range: ?\                                                                                                                                                                                                 SS less adverse events recorded in L‐PRF group (pain, *p* = 0.01; swelling, *p* = 0.02).
                                                                                                   Smoking: ?                                                                                                                                                                                                

  L‐PRF *versus* PRP                                                                                                                                                                                                                                                                                         

  Yelamali & Saikrishna ([2015](#jcpe12658-bib-0045){ref-type="ref"})     RCT\                     20 -- (20)\                                                                          20 bilateral impacted 3rd molar:\      Hardware: ?\                                           1 L‐PRF clot\          **L‐PRF** ***versus*** **PRP**\
                                                                          Split‐mouth\             8 ♀, 12 ♂\                                                                           C: PRP: *n* = 20, PRP filling\         Setting: 3000 r.p.m./10 min.                           0 L‐PRF membrane\      SS better soft tissue healing for L‐PRF group (*p* \< 0.05).
                                                                          Not blind\               Mean age: ?\                                                                         T: L‐PRF: *n* = 20, L‐PRF filling                                                             6 ml blood/clot        
                                                                          4 months                 Range: 21--27\                                                                                                                                                                                            
                                                                                                   Smoking: ?                                                                                                                                                                                                

  L‐PRF pain                                                                                                                                                                                                                                                                                                 

  Marenzi et al. ([2015](#jcpe12658-bib-0026){ref-type="ref"})            RCT\                     26 -- (26)\                                                                          26 bilateral canine/premolar/molar:\   Hardware: [b](#jcpe12658-note-0005){ref-type="fn"}\    2--6 L‐PRF clot\       **L‐PRF pain**\
                                                                          Split‐mouth\             17 ♀, 9 ♂\                                                                           C: *n* = 26, no filling\               Setting: 2700 r.p.m./12 min.                           0 L‐PRF membrane\      SS better and faster healing for L‐PRF group at 3 and 7 days (*p* \< 0.05).\
                                                                          Single‐blind\            Mean age: 53 ± 4\                                                                    T: *n* = 26, L‐PRF filling                                                                    9 ml blood/clot        SS less post‐extraction pain for L‐PRF group (*p* \< 0.05).
                                                                          7 days                   Range: ?\                                                                                                                                                                                                 
                                                                                                   Smoking: No or light smokers (\<5/day)                                                                                                                                                                    

  L‐PRF uptake technetium‐99 m methylene diphosphonate                                                                                                                                                                                                                                                       

  Gürbüzer et al. ([2010](#jcpe12658-bib-0017){ref-type="ref"})           RCT\                     20 -- (14)\                                                                          14 bilateral impacted 3rd molar:\      Hardware : [c](#jcpe12658-note-0006){ref-type="fn"}\   1 L‐PRF clot\          **L‐PRF scintigraphic analysis**\
                                                                          Split‐mouth\             7 ♀, 7 ♂\                                                                            C: *n* = 14, no filling\               Setting: 400 g/10 min.                                 0 L‐PRF membrane\      NSSD in technetium‐99 m methylene diphosphonate uptake (as indicator of enhanced bone healing): L‐PRF 4.5 ± 1.0 *versus* control 4.6 ± 1.0)
                                                                          Not blind\               Mean age: 24 ± 4\                                                                    T: *n* = 14, L‐PRF filling                                                                    10 ml blood/clot       
                                                                          4 weeks                  Range: ?\                                                                                                                                                                                                 
                                                                                                   Smoking: No                                                                                                                                                                                               

  Baslarli et al. ([2015](#jcpe12658-bib-0004){ref-type="ref"})           RCT\                     20 -- (20)\                                                                          20 bilateral impacted 3rd molar:\      Hardware : ?\                                          0 L‐PRF clot\          **L‐PRF scintigraphic analysis**\
                                                                          Parallel\                13 ♀, 7 ♂\                                                                           C: *n* = 20, no filling\               Setting: 3000 r.p.m./10 min.                           1 L‐PRF membrane\      NSSD in technetium‐99 m methylene diphosphonate uptake (as indicator of enhanced bone healing) at 3 months: L‐PRF 4.1 ± 1.0 *versus* 3.9 ± 1.1).
                                                                          Single‐blind\            Mean age: 23\                                                                        T: *n* = 20, L‐ PRF filling                                                                   9 ml blood/clot        
                                                                          3 months                 Range: 10--34\                                                                                                                                                                                            
                                                                                                   Smoking: No                                                                                                                                                                                               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

C, control group; L‐PRF, leucocyte‐ and platelet rich fibrin; NSSD, no statistically significant difference; PD, Pocket depth; RCT, randomized control trials; SS, statistically significant; *T*, test group.

^a^EBA 20, Hettich GmbH&Co, KG, Tuttlingen, Germany.

^b^Intra‐Spin L‐PRF kit, Intra‐Lock, Boca‐Raton, FL, USA.

^c^Universal 320 Hettich, Tuttlingen, Germany.

John Wiley & Sons, Ltd

###### 

L‐PRF for implant therapy. Papers have been arranged by sub‐applications (L‐PRF at implant placement, L‐PRF in peri‐implant defects)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors (year)                                                     Study design, Duration   No. of participants baseline (end), gender, age (mean/range), Smoking (?, No, Yes)   Groups C: control *T*: test   L‐PRF preparation                                     Surgical protocol                         Results
  ------------------------------------------------------------------ ------------------------ ------------------------------------------------------------------------------------ ----------------------------- ----------------------------------------------------- ----------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  L‐PRF at implant placement                                                                                                                                                                                                                                                                                     

  Boora et al. ([2015](#jcpe12658-bib-0006){ref-type="ref"})         RCT\                     20 -- (20)\                                                                          C: *n* = 10, no L‐PRF\        Hardware: ?\                                          1 L‐PRF membrane\                         **L‐PRF at implant placement**\
                                                                     Parallel\                5 ♀, 15 ♂\                                                                           T: *n* = 10, L‐PRF            Setting: 3000 r.p.m./10--12 min.                      Adin Dental Implant System (Israel)\      SS less initial marginal bone loss for L‐PRF group at mesial and distal site (L‐PRF 0.3 ± 0.06 mm, 0.3 ± 0.02 mm control 0.6 ± 0.02 mm, 0.7 ± 0.08 mm) (*p* \< 0.001). NSSD for PD (*p* \> 0.05) and BoP (*p* \> 0.05).
                                                                     Not blind\               Mean age: 25 ± ?\                                                                                                                                                        10--14 days non‐functional prov. crown\   
                                                                     3 months                 Range: 18--33\                                                                                                                                                           10 ml blood/clot                          
                                                                                              Smoking: ?                                                                                                                                                                                                         

  Öncü & Alaadinŏglu ([2015](#jcpe12658-bib-0032){ref-type="ref"})   RCT\                     20 -- (20)\                                                                          C: *n* = 33, no L‐PRF\        Hardware: [a](#jcpe12658-note-0009){ref-type="fn"}\   1 L‐PRF membrane + exudate\               **L‐PRF at implant placement**\
                                                                     Parallel\                6 ♀, 14 ♂\                                                                           T: *n* = 31, L‐PRF            Setting: 2700 r.p.m./12 min.                          Ankylos Implant System (Dentsply)\        SS higher ISQ values for L‐PRF group by the end of the 1st week (69 *versus* 64) (*p* \< 0.05) and 4th week (77 *versus* 70.5) (*p* = 0.001).\
                                                                     Not blind\               Mean age: 44 ± 12\                                                                                                                                                       no imm. function\                         Mean ISQ values in L‐PRF group increased continuously.
                                                                     1 month                  Range: ?\                                                                                                                                                                10 ml blood/clot                          
                                                                                              Smoking: \<10cig/day                                                                                                                                                                                               

  L‐PRF in peri‐implant defects                                                                                                                                                                                                                                                                                  

  Hamzacebi et al. ([2015](#jcpe12658-bib-0018){ref-type="ref"})     RCT\                     19 -- (19)\                                                                          C: *n* = 19, OFD\             Hardware: ?\                                          1 L‐PRF clot\                             **L‐PRF in peri‐implant defects**\
                                                                     Parallel\                8 ♀, 11 ♂\                                                                           T: *n* = 19, OFD + L‐PRF      Setting: 3000 r.p.m./10 min.                          \>1 L‐PRF membrane\                       SS more PD reduction for L‐PRF group (2.8 ± 1.0 mm *versus* 2.0 ± 0.7 mm) and CAL gain (3.3 ± 1.1 *versus* 1.8 ± 0.8 mm).
                                                                     Not blind\               Mean age: 61 ± 12\                                                                                                                                                       Type implant not mentioned\               
                                                                     6 months                 Range: ?\                                                                                                                                                                imm. function\                            
                                                                                              Smoking: ?                                                                                                                                                               10 ml blood/clot                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BoP, bleeding on probing; C, control group; CAL, clinical attachment level; imm. function, immediate function; ISQ, implant stability quotient; L‐PRF, leucocyte‐ and platelet‐rich fibrin; PD, pocket depth; RCT, randomized control trials; SS, statistically significant; *T*, test group.

^a^PC‐02, Process Ldt.

John Wiley & Sons, Ltd

Sinus floor elevation procedures (SFE): *n* = 3, Tatullo et al. ([2012](#jcpe12658-bib-0042){ref-type="ref"}), Zhang et al. ([2012](#jcpe12658-bib-0046){ref-type="ref"}) and Gassling et al. ([2013](#jcpe12658-bib-0016){ref-type="ref"}).Alveolar ridge preservation: *n* = 8, Gürbüzer et al. ([2010](#jcpe12658-bib-0017){ref-type="ref"}), Singh et al. ([2012](#jcpe12658-bib-0039){ref-type="ref"}), Hauser et al. ([2013](#jcpe12658-bib-0019){ref-type="ref"}), Suttapreyasri & Leepong ([2013](#jcpe12658-bib-0040){ref-type="ref"}), Baslarli et al. ([2015](#jcpe12658-bib-0004){ref-type="ref"}), Marenzi et al. ([2015](#jcpe12658-bib-0026){ref-type="ref"}), Kumar et al. ([2015](#jcpe12658-bib-0023){ref-type="ref"}) and Yelamali & Saikrishna ([2015](#jcpe12658-bib-0045){ref-type="ref"}).Implant therapy: *n* = 3, Boora et al. ([2015](#jcpe12658-bib-0006){ref-type="ref"}), Hamzacebi et al. ([2015](#jcpe12658-bib-0018){ref-type="ref"}) and Öncü & Alaadinŏglu ([2015](#jcpe12658-bib-0032){ref-type="ref"}).

Assessment of heterogeneity {#jcpe12658-sec-0014}
---------------------------

### Study design and evaluation period {#jcpe12658-sec-0015}

All studies were RCTs and often a split‐mouth design was applied. The following articles fulfilled both study designs: SFE 1/3 (Gassling et al. [2013](#jcpe12658-bib-0016){ref-type="ref"}), ridge preservation 4/8 (Gürbüzer et al. [2010](#jcpe12658-bib-0017){ref-type="ref"}, Singh et al. [2012](#jcpe12658-bib-0039){ref-type="ref"}, Marenzi et al. [2015](#jcpe12658-bib-0026){ref-type="ref"}, Yelamali & Saikrishna [2015](#jcpe12658-bib-0045){ref-type="ref"}), and implant therapy 0/3. The follow‐up ranged considerably (SFE 5--6 months, ridge preservation 7 days to 4 months, implant therapy 1--6 months).

### Subject characteristics and smoking habits {#jcpe12658-sec-0016}

Healthy subjects with no active periodontal disease were included in all the studies. The articles that exclude the smokers are the following: SFE 1/3 (Tatullo et al. [2012](#jcpe12658-bib-0042){ref-type="ref"}), ridge preservation 4/8 (Gürbüzer et al. [2010](#jcpe12658-bib-0017){ref-type="ref"}, Singh et al. [2012](#jcpe12658-bib-0039){ref-type="ref"}, Baslarli et al. [2015](#jcpe12658-bib-0004){ref-type="ref"}, Marenzi et al. [2015](#jcpe12658-bib-0026){ref-type="ref"}), and implant therapy 0/3. However, in alveolar ridge preservation and implant therapy, most of the studies did not mention the smoking status (ridge preservation 4/8 (Hauser et al. [2013](#jcpe12658-bib-0019){ref-type="ref"}, Suttapreyasri & Leepong [2013](#jcpe12658-bib-0040){ref-type="ref"}, Kumar et al. [2015](#jcpe12658-bib-0023){ref-type="ref"}, and Yelamali & Saikrishna [2015](#jcpe12658-bib-0045){ref-type="ref"}), and implant therapy 2/3 (Boora et al. [2015](#jcpe12658-bib-0006){ref-type="ref"}, Hamzacebi et al. [2015](#jcpe12658-bib-0018){ref-type="ref"}).

### Surgical protocol {#jcpe12658-sec-0017}

This heterogeneity in the surgical protocols is shown in Tables [1](#jcpe12658-tbl-0001){ref-type="table-wrap"}, [2](#jcpe12658-tbl-0002){ref-type="table-wrap"}, [3](#jcpe12658-tbl-0003){ref-type="table-wrap"}.

Data extraction {#jcpe12658-sec-0018}
---------------

The variables processed as primary outcome were mean newly formed bone (%) for the SFE subgroup; soft tissue and bone healing (reported as healing index scores, bone resorption in mm and/or in technetium‐99 m methylene diphosphonate uptake) for alveolar ridge preservation; and peri‐implant bone stability (ISQ values and/or marginal bone loss in mm) for implant therapy. Post‐operative pain was considered as secondary outcome. All the data presented a high heterogeneity, so a meta‐analysis was impossible. The follow‐up also differed substantially, therefore a comparison between studies was difficult.

### Sinus floor elevation {#jcpe12658-sec-0019}

All included studies used L‐PRF in combination with a xenograft material and compared it to the xenograft alone (Table [1](#jcpe12658-tbl-0001){ref-type="table-wrap"}). One study compared, in a split‐mouth set‐up, an L‐PRF membrane with a collagen membrane to cover a lateral window and reported a similar outcome in terms of percentage of mean vital bone formation and residual xenograft (Gassling et al. [2013](#jcpe12658-bib-0016){ref-type="ref"}). Zhang et al. ([2012](#jcpe12658-bib-0046){ref-type="ref"}) evaluated the addition of L‐PRF to the xenograft during a lateral window sinus augmentation. They observed 1.4 times more percentage of newly formed bone in the L‐PRF group. Also, when L‐PRF was used in a trans‐alveolar approach, histologically, a faster bone healing was observed (Tatullo et al. [2012](#jcpe12658-bib-0042){ref-type="ref"}). Due to the heterogeneity of the data, meta‐analysis could not be conducted.

### Alveolar ridge preservation {#jcpe12658-sec-0020}

In general, L‐PRF improved the preservation of the alveolar ridge and resulted in less buccal bone resorption compared to the natural healing (Singh et al. [2012](#jcpe12658-bib-0039){ref-type="ref"}, Hauser et al. [2013](#jcpe12658-bib-0019){ref-type="ref"}, Suttapreyasri & Leepong [2013](#jcpe12658-bib-0040){ref-type="ref"}, Kumar et al. [2015](#jcpe12658-bib-0023){ref-type="ref"}). A better soft tissue healing and less post‐extraction pain was frequently reported (Singh et al. [2012](#jcpe12658-bib-0039){ref-type="ref"}, Hauser et al. [2013](#jcpe12658-bib-0019){ref-type="ref"}, Kumar et al. [2015](#jcpe12658-bib-0023){ref-type="ref"}, Marenzi et al. [2015](#jcpe12658-bib-0026){ref-type="ref"}). However, scintigraphic analyses (after 4 and 8 weeks) did not show enhanced bone healing in L‐PRF sites (Table [2](#jcpe12658-tbl-0002){ref-type="table-wrap"}). The wide variability of the data did not allow a meta‐analysis. Most studies used only one L‐PRF clot/membrane per extraction site, which might be insufficient.

The adverse events were only registered in four out of the eight articles within this group. Each article analysed the adverse events with a different scale, so no meta‐analysis could be performed. In all of them, less pain for L‐PRF sites compared to control sites was reported (Singh et al. [2012](#jcpe12658-bib-0039){ref-type="ref"}, Hauser et al. [2013](#jcpe12658-bib-0019){ref-type="ref"}, Kumar et al. [2015](#jcpe12658-bib-0023){ref-type="ref"}, Marenzi et al. [2015](#jcpe12658-bib-0026){ref-type="ref"}).

### Implant therapy {#jcpe12658-sec-0021}

The RCTs (Hamzacebi et al. [2015](#jcpe12658-bib-0018){ref-type="ref"}, Öncü & Alaadinŏglu [2015](#jcpe12658-bib-0032){ref-type="ref"}) evaluated the benefits of the application of L‐PRF on the osseointegration process (Table [3](#jcpe12658-tbl-0003){ref-type="table-wrap"}). Öncü & Alaadinŏglu ([2015](#jcpe12658-bib-0032){ref-type="ref"}) evaluated the impact of implant coating with L‐PRF. Implant stability was measured through resonance frequency analysis with implant stability quotients (ISQ values). The use of L‐PRF at implant insertion resulted in statistically significant higher ISQ values which increased continuously over time. Boora et al. ([2015](#jcpe12658-bib-0006){ref-type="ref"}) recorded the early bone remodelling around implants coated or not with L‐PRF at insertion. The L‐PRF‐coated implants showed 50% less initial bone loss. Both after 1 and 3 months, respectively, (at 3 months: L‐PRF sites: 0.3 ± 0.6 mm mesially and 0.3 ± 0.7 mm distally, non‐L‐PRF site: 0.6 ± 0.2 mm mesially and 0.7 ± 0.3 mm distally). Hamzacebi et al. ([2015](#jcpe12658-bib-0018){ref-type="ref"}) assessed the effectiveness of the application of L‐PRF and conventional flap surgery for the treatment of peri‐implantitis bone loss. They reported more PD reduction (at 3 and 6 months: L‐PRF sites: 2.4 ± 1.1 mm and 2.8 ± 1.0 mm, non‐L‐PRF sites: 1.65 ± 1.0 mm and 2.0 ± 0.7 mm), and CAL gain (L‐PRF sites: 2.9 ± 1.0 mm, non‐L‐PRF sites: 1.4 ± 1.0 mm).

Quality assessment {#jcpe12658-sec-0022}
------------------

All articles on SFE and implant therapy showed a moderate risk of bias. Six articles using L‐PRF for alveolar ridge preservation had a moderate risk and two had a high risk of bias. Appendix S1 shows the quality assessment for the included studies.

For the groups of SFE and alveolar ridge preservation, a good inter‐rate agreement or weighted kappa was found (0.67, 95% CI, 0.4--0.9, and 0.63, 95% CI, 0.5--0.8 respectively). A fair inter‐rate agreement (0.55, 95% CI, 0.2--0.9) was observed for the group of implant therapy. In the latest, the most disagreement was on the "incomplete outcome data" and "selective outcome reporting".

Discussion {#jcpe12658-sec-0023}
==========

In recent years, L‐PRF has been used in sinus floor elevation (SFE) either as a sole filling material or in combination with other graft materials. As mentioned in the results section, when L‐PRF was used in combination with a graft material, better results were often obtained. However, no RCT or controlled clinical trial (CCT) could be retrieved in which L‐PRF was used as the sole filling material or in combination with autologous bone grafts. The use of L‐PRF as sole filling material has been analysed in several case series and case reports. In these studies, L‐PRF was always used in combination with implant placement so that the implants could maintain the sinus membrane in an elevated position. Using the lateral window technique, Mazor et al. ([2009](#jcpe12658-bib-0029){ref-type="ref"}), Simonpieri et al. ([2011](#jcpe12658-bib-0038){ref-type="ref"}) and Tajima et al. ([2013](#jcpe12658-bib-0041){ref-type="ref"}) evaluated the effectiveness of L‐PRF as a sole graft material in SFE with simultaneous implant placement. In the first two articles, a bone gain of 7.5 mm (SD not mentioned) and 10.1 mm ± 0.9 mm, respectively, at 6 months was reported. Tajima et al. ([2013](#jcpe12658-bib-0041){ref-type="ref"}) found a bone gain of 10.4 mm ± 1.2 at 1‐year follow‐up. They all concluded that L‐PRF as a sole filling material could promote natural bone regeneration producing dense bone‐like tissue, at least when implants are placed simultaneously. L‐PRF has also been used as the sole filling material in a transalveolar approach. Using this approach, the case series of Diss et al. ([2008](#jcpe12658-bib-0010){ref-type="ref"}) reported that a healing period of 2--3 months was sufficient to resist a torque of 25 Ncm applied during abutment tightening. At 1‐year follow‐up, formation of a new recognizable bone structure delimiting the sinus floor was identified radiographically. Toffler et al. ([2010](#jcpe12658-bib-0043){ref-type="ref"}) reported on 110 cases of osteotome‐mediated SFE, with L‐PRF as sole filling material during implant placement. The mean increase in the height at implant sites was 3--4 mm (range 2.5--5 mm), similar to the traditional osteotomes procedures. In a recent study (Kanayama et al. [2016](#jcpe12658-bib-0021){ref-type="ref"}), the mean bone gain around two different types of implant surfaces \[hydroxyapatite (HA) and sandblasted acid‐etched (SA)\] was analysed using L‐PRF as sole filling material in a transalveolar approach. Similar bone gain around both implant surfaces was reported (4.0 ± 1.6 mm and 4.4 ± 1.7 mm respectively) after 1‐year follow‐up. The main challenge in SFE procedures is to avoid the perforation of the Schneiderian membrane (Pjetursson & Lang [2014](#jcpe12658-bib-0034){ref-type="ref"}). It has been reported that L‐PRF can be used to cover the perforation since it has a good intrinsic adherence to the Schneiderian membrane. Consequently, it can also be used preventively to reduce the risk of perforation during SFE procedures (Simonpieri et al. [2011](#jcpe12658-bib-0038){ref-type="ref"}).

L‐PRF has been applied after tooth extraction to prevent bone resorption and alveolar ridge collapse. Most studies confirmed that L‐PRF decreased the healing time as well as reduced the resorption of the buccal plate. However, five out of the eight studies evaluated the use of L‐PRF in third molar extraction sites, which might have a distinct healing process when compared to extraction sites in the aesthetic region. Moreover, most of the studies used only one L‐PRF clot or membrane to fill the extraction socket. One could question whether one clot or membrane is sufficient to completely fill the alveolus in order to create an adequate environment to stimulate the migration of osteoblasts and endothelial cells. The use of an L‐PRF membrane on top, to close the alveolar socket, might have a significant influence on the outcome. Also, the amount of cells brought to the surgical site, as well as the quantity of fibrin might be crucial for success.

Although the application of L‐PRF during implant placement or for the treatment of peri‐implant defects is quite new, several studies already showed clinical benefits (higher ISQ values, less marginal bone resorption). Lee et al. ([2012](#jcpe12658-bib-0024){ref-type="ref"}) revealed in an animal study more bone‐to‐implant contact (39.4% ± 7.4 *versus* 17.1% ± 8.1) after the treatment of peri‐implantitis defects with L‐PRF.

Some limitations are needed to be taken into account regarding this systematic review. Most of the included articles showed a moderate risk of bias and some even a high risk. In this last case, the allocation concealment was not correctly applied what increased the risk of bias. In addition, no meta‐analysis could be performed in any of the groups due to the heterogeneity of the data. Therefore, this systematic review can only analyse the included articles qualitatively. Consequently, the varied nature of the data resulted in a lack of strong evidence for this systematic review.

However, it is also worth to highlight the strengths. A total number of 296 participants were enrolled in the selected studies (161 in alveolar ridge preservation, 76 in sinus floor elevation and 59 in implant therapy). The surgical protocol of all these studies was examined, giving a detailed information about the use of L‐PRF in each application. Consequently, we could observe that to use the correct protocol is extremely important to obtain an optimal effect.

L‐PRF should be certainly distinguished from other types of platelet concentrates. The architecture of the fibrin matrix and its cellular content differ from the other products, as well as the biological activity.

Conclusion {#jcpe12658-sec-0024}
==========

Despite the lack of strong evidence found in the included articles, beneficial effects on bone regeneration and in implant surgery are suggested when L‐PRF is applied. Given its ease of preparation, low cost and biological properties, L‐PRF could be considered as a reliable option of treatment. However, standardization of the protocol is required to obtain reproducible results. The use of enough L‐PRF clots or membranes seems to be crucial to obtain an optimal effect.

Due to the lack in the standardization of the study design and variables analysed, further RCTs with long‐term follow‐up are needed to assess the beneficial effect of L‐PRF on bone augmentation procedures and osseointegration.

 {#jcpe12658-sec-0026}

Clinical Relevance*Scientific rationale for the study*: The aim of this systematic review was to analyse the effect of L‐PRF on bone regeneration and osseointegration.*Principal findings*: When L‐PRF was added to a bone substitute during sinus floor elevation bone healing occurred faster. L‐PRF, alone or combined with bone substitutes, improved the preservation of the alveolar ridge compared to natural healing. In implant therapy, better implant stability over time and less marginal bone loss were reported after the use of L‐PRF.*Practical implications*: Though there is a lack of strong evidence, these results showed favourable effects of L‐PRF on bone regeneration and osseointegration.
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